Talazoparib
- Generic Name
- Talazoparib
- Brand Names
- Talzenna
- Drug Type
- Small Molecule
- Chemical Formula
- C19H14F2N6O
- CAS Number
- 1207456-01-6
- Unique Ingredient Identifier
- 9QHX048FRV
- Background
Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair.
...
- Indication
Talazoparib is indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative locally advanced or metastatic breast cancer. This indication is approved by the FDA, EMA, and Health Canada.
...
- Associated Conditions
- HRR gene-mutated (HRRm) metastatic castration-resistant prostate cancer (mCRPC), Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Associated Therapies
- -
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06218628
- Locations
- 🇺🇸
Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania, United States
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 66
- Registration Number
- NCT06193525
- Locations
- 🇳🇱
Groningen University Medical Center, Groningen, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
🇳🇱Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05873192
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT05725200
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)
- First Posted Date
- 2022-12-14
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Pfizer
- Registration Number
- NCT05650476
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 48
- Registration Number
- NCT05425862
- Locations
- 🇦🇺
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇦🇺Box Hill Hospital, Box Hill, Victoria, Australia
🇦🇺Royal Melbourne Hospital, Melbourne, Victoria, Australia
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 88
- Registration Number
- NCT05327010
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature
- Conditions
- Interventions
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- University of Malaya
- Target Recruit Count
- 55
- Registration Number
- NCT05288127
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 34
- Registration Number
- NCT05142241
- Locations
- 🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 33
- Registration Number
- NCT05141708
- Locations
- 🇺🇸
Pfizer Inc., New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.